5 results on '"Magina S"'
Search Results
2. Oral isotretinoin in the treatment of juvenile acne and psychiatric adverse effects - a systematic review.
- Author
-
Fernandes T and Magina S
- Subjects
- Adolescent, Young Adult, Humans, Isotretinoin adverse effects, Anxiety, Treatment Outcome, Acne Vulgaris drug therapy, Drug-Related Side Effects and Adverse Reactions, Dermatologic Agents adverse effects
- Abstract
Purpose: Acne vulgaris is a very prevalent dermatological condition, especially among adolescents and young adults up to 25 years old, classifying it as juvenile acne. One of the most effective treatments for severe acne is isotretinoin, a derivative of retinoic acid. Despite its high efficacy, this drug has been linked to several side effects including psychiatric adverse alterations, such as anxiety, depression and even suicide. With this systematic review we aim to determine if it is possible to establish a causal relation between oral isotretinoin in the treatment of juvenile acne and the appearance of psychiatric adverse effects., Materials and Methods: We searched two distinct databases, PubMed and Web of Science, and considered the work published between January 2000 and November 2021., Results: Out of the 599 identified articles, we included 19 studies in this systematic review. Globally, the results we found do not support an association between the use of isotretinoin for acne treatment and mental side effects and the safety of this drug appears to be assured. However, the individual characteristics of each adolescent and their environment should be considered; the personal and family history of mental disorders are pointed out as red flags we should look out for when treating these patients., Conclusion: Despite this being a highly debated topic, especially among the dermatology community, more studies with larger populations and randomised controlled trials are necessary to increase the strength of the evidence presented.
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
- Author
-
Melo FJ and Magina S
- Subjects
- Adalimumab adverse effects, Algorithms, Certolizumab Pegol adverse effects, Dermatologic Agents adverse effects, Feces chemistry, Humans, Inflammatory Bowel Diseases metabolism, Infliximab adverse effects, Leukocyte L1 Antigen Complex analysis, Tumor Necrosis Factor-alpha antagonists & inhibitors, Ustekinumab therapeutic use, Dermatologic Agents therapeutic use, Gastrointestinal Agents adverse effects, Inflammatory Bowel Diseases drug therapy, Psoriasis chemically induced, Psoriasis drug therapy
- Abstract
Tumor necrosis factor alpha inhibitors (anti-TNF-α) completely revolutionized the treatment of inflammatory bowel disease (IBD). However, anti-TNF-α-induced cutaneous side effects have been increasingly reported in the literature. Particularly, psoriasis and the recently recognized psoriasiform lesions are of particular concern, as anti-TNF-α agents are also used in the treatment of psoriasis, seemingly reflecting an immunological paradox. The clinical management of these cutaneous lesions is particularly challenging, owing to the potential need of anti-TNF-α discontinuation and scarcity of other therapeutic options. Therefore, optimization of current topical and systemic therapies and incorporation of new therapeutic agents is of great interest. Our aim is to review data in the literature regarding the clinical management of these cutaneous lesions and provide a therapeutic algorithm, supported by our experience as a tertiary referral center for IBD. Although in older reports no distinction was made, anti-TNF-α-induced psoriasiform lesions are not only more prevalent but also bear notable differences from classical psoriasis, possibly reflecting a different nosological entity. Onset of lesions has been related to periods of IBD remission, as supported by low levels of fecal calprotectin. Psoriasiform lesions can be adequately managed either by topical (glucocorticoids, calcineurin inhibitors, and antibiotics) or systemic (phototherapy, acitretin, glucocorticoids, and antibiotics) therapies and/or switch to other anti-TNF-α agents. Data referring to patients who were able to continue on the same IBD therapy ranged from 30.7 to 100%, reinforcing the importance of an adequate control of these lesions. The recently approved ustekinumab offers another step in the management of anti-TNF-α-intolerant patients., (© 2018 The International Society of Dermatology.)
- Published
- 2018
- Full Text
- View/download PDF
4. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.
- Author
-
Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, and Thaci D
- Subjects
- Administration, Topical, Dermatologic Agents administration & dosage, Drug Compounding, Humans, Treatment Outcome, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Abstract
Although the majority of patients with psoriasis vulgaris are treated exclusively with topical therapies, research to develop more effective topical therapies that are associated with higher patient satisfaction has lagged behind the development of systemic agents. The aim of this literature review was to determine whether there is documented evidence that applying an innovative approach to improving the formulation of active ingredients commonly used in the topical treatment of psoriasis can have a positive effect on clinical outcomes and patient-reported outcomes (PROs). The Embase and PubMed databases were searched for articles published between 2001 and 2016 that made direct head-to-head comparisons of different formulations of an active pharmaceutical ingredient (API), focusing on clinical outcomes and PROs. In total, 22 publications on APIs or API combinations met the eligibility criteria (19 head-to-head clinical trials, one pooled analysis, one health-economic modelling study and one systematic review). Significant clinical benefit associated with the use of a reformulated API over an older formulation was reported in three trials of clobetasol propionate, one trial of calcipotriol, three trials of betamethasone and five trials/pooled analyses of calcipotriol/calcipotriene + betamethasone dipropionate (Cal/BD) formulations. Significantly improved PROs associated with the use of a reformulated API over an older formulation were reported in three trials of clobetasol propionate, one trial of betamethasone valerate and two trials of Cal/BD formulations. These results demonstrate that the innovative reformulation of APIs used in the treatment of psoriasis can produce therapies that attain significantly improved clinical outcomes and PROs. This suggests that improvement in topical therapy for psoriasis need not only to be achieved by the identification of new targets and the development of new APIs, but that improvement in the vehicle used to deliver existing APIs has the potential to result in significant clinical and patient benefits., (© 2017 European Academy of Dermatology and Venereology.)
- Published
- 2017
- Full Text
- View/download PDF
5. Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy.
- Author
-
Magina S, Santos J, Coroas A, Oliveira JG, Serrão P, Soares-Da-Silva P, Resende C, and Pestana M
- Subjects
- Adult, Blood Pressure drug effects, Female, Humans, Male, Middle Aged, Natriuresis physiology, Norepinephrine blood, Norepinephrine urine, Psoriasis physiopathology, Blood Pressure physiology, Cyclosporine adverse effects, Dermatologic Agents adverse effects, Immunosuppressive Agents adverse effects, Psoriasis drug therapy, Sodium, Dietary administration & dosage
- Abstract
Background: Hypertension is one of the main side-effects of long-term therapy with ciclosporin. However, the influence of salt intake on the 24-h mean blood pressure of patients with psoriasis treated with ciclosporin is not known., Objectives: To evaluate, in patients with psoriasis, the sodium sensitivity of the ciclosporin-induced rise in blood pressure., Methods: The 24-h ambulatory blood pressure was evaluated in 13 patients with psoriasis (age range 20-57 years) in two phases, before (phase I) and after the completion of 4 months of therapy with ciclosporin 3 mg kg(-1) daily (phase II). In both phases, the patients were studied in conditions of low sodium (LS) intake followed by a high sodium (HS) diet., Results: Twenty-four-hour mean +/- SD blood pressure during LS and HS intake was, respectively, 86.3 +/- 1.6 mmHg and 85.5 +/- 1.8 mmHg during phase I, and 88.5 +/- 1.5 mmHg and 91.8 +/- 2.2 mmHg (P < 0.001 vs. phase I, HS; P < 0.05 vs. phase II, LS) during phase II. The median (interquartile range) sodium sensitivity index was greater during phase II than during phase I: - 0.0028 (- 0.0071 to 0.0009) vs. 0.0065 (- 0.0055 to 0.0258) (P < 0.02). The plasma levels and the daily urinary excretion of noradrenaline did not differ between phases I and II., Conclusions: The ciclosporin-induced rise in blood pressure is sodium sensitive. It is also suggested that sympathetic activation is not involved in the pathogenesis of ciclosporin-induced rise in blood pressure.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.